Deciphering the multidrug resistance paradigm in Candida auris

Area of Science:

• Medical Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Candida auris is a multidrug-resistant fungal pathogen of global health concern.
• Rising antifungal resistance in C. auris threatens treatment options, leading to untreatable infections.
• Existing antifungal drugs face challenges from pan-resistant C. auris isolates.

Purpose of the Study:

• To review recent literature on resistance mechanisms and evolution in clinical C. auris isolates.
• To propose a refined model of C. auris drug resistance by drug class.
• To identify potential therapeutic strategies based on unique resistance patterns.

Main Methods:

• Literature review of recent studies on C. auris antifungal resistance.
• Analysis of resistance mechanisms for fluconazole, echinocandins, amphotericin B, and flucytosine.
• Examination of evolutionary patterns and clade-specific resistance.

Main Results:

• Fluconazole resistance is linked to target mutations and efflux regulator alterations, with potential vulnerabilities to other triazoles.
• Acquired resistance to echinocandins, amphotericin B, and flucytosine is rare but emerges via conserved mechanisms.
• Higher amphotericin B resistance in C. auris compared to other Candida species may involve intrinsic mechanisms.

Conclusions:

• Separating resistance challenges by drug class offers a refined model for C. auris drug resistance.
• Understanding specific resistance mechanisms may guide the use of existing antifungals.
• Further investigation into C. auris resistance mechanisms is crucial for developing effective treatments.